Please login to the form below

Not currently logged in
Email:
Password:

NSCLC

This page shows the latest NSCLC news and features for those working in and with pharma, biotech and healthcare.

AZ’s Imfinzi combo bombs again in non-small cell lung cancer

AZ’s Imfinzi combo bombs again in non-small cell lung cancer

as a maintenance therapy for locally-advanced NSCLC patients whose tumours cannot be removed surgically. ... Meanwhile, the PEARL trial is pitting Imfinzi against chemotherapy in first-line NSCLC.

Latest news

  • Roche undercuts price of Bayer cancer drug after winning FDA approval Roche undercuts price of Bayer cancer drug after winning FDA approval

    The approval clears Roche’s Rozlytrek (entrectinib) for use in adults with ROS1-positive, metastatic non-small cell lung cancer (NSCLC) and people aged 12 and over with solid tumours that ... Rozlytrek achieved overall response rates of 78% and 57% in

  • Tagrisso tops rival drugs on survival in first-line lung cancer Tagrisso tops rival drugs on survival in first-line lung cancer

    Updated results from the FLAURA trial show that Tagrisso extends survival in previously-untreated patients with EGFR-positive non-small cell lung cancer (NSCLC), building on 2017 results showing that the ... AZ’s head of oncology José Baselga.

  • Triplet approvals for myeloma boost Celgene in Q2 Triplet approvals for myeloma boost Celgene in Q2

    Abraxane is enjoying a sales surge thanks to its use in combination with cancer immunotherapies in indications like non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC), according

  • CHMP backs Bayer’s tumour-agnostic drug Vitrakvi CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

    for previously-untreated patients with non-squamous NSCLC. ... The approval, based on the results of the IMpower130 trial, could help Roche try to build in first-line NSCLC, an indication dominated by Merck &Co’s Keytruda (pembrolizumab).

  • Opdivo trial overshadows BMS financial results Opdivo trial overshadows BMS financial results

    BMS has been desperate to come up with an Opdivo (nivolumab) study that can expand use of the drug into first-line non-small cell lung cancer (NSCLC), a category comprehensively ... Unfortunately for BMS, in a second part of the study Opdivo plus

More from news
Approximately 123 fully matching, plus 341 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 1 fully matching, plus 12 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics